SCHEMBL19687525

SCHEMBL19687525

Cc1cc(C)n(-c2cc(C(=O)O)cc(NC3CCC(F)(F)CC3)n2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.44
KCNN3 Q9UGI6 1/20 0.44
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
IDH1 O75874 2/20 0.37
NR2F2 P24468 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
ADORA2A P29274 5/20 0.36
ADORA1 P30542 5/20 0.36
KCNH2 Q12809 2/20 0.36
HCAR3 P49019 1/20 0.36
PTGER4 P35408 1/20 0.36
NPC1 O15118 1/20 0.36
S1PR2 O95136 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31127116 1.00 KCNN2 (0.44) KCNN2KCNN3MEN1KMT2ACYP2C9
SCHEMBL19686939 0.91 KCNN2 (0.43) KCNN2KCNN3MEN1KMT2AIDH1
SCHEMBL21143966 0.89 KCNN2 (0.41) KCNN2KCNN3MEN1KMT2ACYP2C9
SCHEMBL31127218 0.89 KCNN2 (0.41) KCNN2KCNN3MEN1KMT2ACYP2C9
SCHEMBL19687523 0.87 NPSR1 (0.47) KCNN2KCNN3MEN1KMT2ACYP2C9
SCHEMBL19686887 0.86 KCNN2 (0.48) KCNN2KCNN3MEN1KMT2AIDH1
SCHEMBL19686284 0.85 KCNN2 (0.49) KCNN2KCNN3HSD17B10IDH1MAPT
SCHEMBL19686732 0.83 KCNN3 (0.47) KCNN2KCNN3MEN1KMT2ACYP2C9
SCHEMBL21144072 0.82 IDH1 (0.39) IDH1MAPTMAPK1HCAR3PTGER4
SCHEMBL31127405 0.82 IDH1 (0.39) IDH1MAPTMAPK1HCAR3PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885MEN1 1514/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885MEN1 1514/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885MEN1 1514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.